---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044160"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:49:09.658629+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026

## Summary
- Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.
- Revenue fell to $0.4M from $1.8M due to PUR1900 wind down; R&D expenses cut 80% to $0.8M.
- Cash and equivalents $10.8M; company expects funding into Q4 2026.
- Completed wind down of PUR1900 Phase 2b; no further financial obligation, to receive 2% royalties ex-US.
- Closed MannKind cross-license for iSPERSE technology; pursuing strategic alternatives.

## SEC filing metadata
- accession: 0001493152-24-044160
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315224044160/0001493152-24-044160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315224044160/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044160
- JSON: https://secwatch.observer/filing/0001493152-24-044160.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.